Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML

Abstract: This phase 1 study investigated the addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy with cytarabine, daunorubicin, and midostaurin in 21 patients with newly diagnosed (ND) FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). Four dose levels of GO were e...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jayanshu Jain, Kelly Pugh, Shivani Handa, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel Cook, Jennifer Saultz, Ronan Swords, Junyang Li, George S. Laszlo, Nicole R. Grieselhuber, Alice S. Mims, Karilyn T. M. Larkin, Kieran Sahasrabudhe, James S. Blachly, Gregory K. Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L. Koenig, Uma Borate
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-02-01
Col·lecció:	Blood Neoplasia
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2950328025001062
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!